Bimekizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bimekizumab
Accession Number
DB12917
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Bimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
UCB4940
Categories
UNII
09495UIM6V
CAS number
1418205-77-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Bimekizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Bimekizumab.
AbrilumabThe risk or severity of adverse effects can be increased when Bimekizumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Bimekizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Bimekizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Bimekizumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Bimekizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimekizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Bimekizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Bimekizumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911408
Wikipedia
Bimekizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentMild to Moderate Psoriasis1
1CompletedTreatmentPsoriatic Arthritis1
1SuspendedBasic ScienceHealthy Study Participants1
2Active Not RecruitingTreatmentAnkylosing Spondylitis (AS)2
2Active Not RecruitingTreatmentPsoriatic Arthritis1
2CompletedTreatmentAnkylosing Spondylitis (AS)1
2CompletedTreatmentChronic Plaque Psoriasis4
2CompletedTreatmentHidradenitis Suppurativa (HS)1
2CompletedTreatmentPsoriatic Arthritis1
2CompletedTreatmentRheumatoid Arthritis1
3Active Not RecruitingTreatmentChronic Plaque Psoriasis / Moderate to Severe Chronic Plaque Psoriasis2
3Active Not RecruitingTreatmentChronic Plaque Psoriasis / Moderate to Severe Chronic Plaque Psoriasis / Psoriatic Arthritis1
3CompletedTreatmentChronic Plaque Psoriasis / Moderate to Severe Chronic Plaque Psoriasis / Psoriatic Arthritis1
3CompletedTreatmentChronic Plaque Psoriasis / Moderate to Severe Plaque Psoriasis1
3Enrolling by InvitationTreatmentPsoriatic Arthritis2
3RecruitingTreatmentChronic Plaque Psoriasis / Moderate to Severe Chronic Plaque Psoriasis1
3SuspendedTreatmentAnkylosing Spondylitis (AS)1
3SuspendedTreatmentHidradenitis Suppurativa (HS)2
3SuspendedTreatmentNonradiographic Axial Spondyloarthritis1
3SuspendedTreatmentPsoriatic Arthritis2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 19:15 / Updated on March 01, 2020 21:21

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates